Flores, Joseph http://orcid.org/0000-0002-4790-3034
Fillion, Marie-Lyne
LeBlanc, Andréa C. http://orcid.org/0000-0003-0418-3900
Funding for this research was provided by:
Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (153097)
Jewish General Hospital
Article History
Received: 16 February 2022
Revised: 21 September 2022
Accepted: 22 September 2022
First Online: 11 October 2022
Competing interests
: The authors declare the following competing interests. Andrea LeBlanc is the Founder and President of CASP-AID INC., a private biotech start-up company whose goal is to develop treatments against cognitive impairment, including drugs that target the Nlrp1-Casp1-Casp6 pathway. Andrea LeBlanc is the controlling shareholder of CASP-AID INC. A patent application entitled “Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions” has been submitted by Andrea LeBlanc (Applicant). The United States Trade and Patent Office has issued Patent 11,160,788 entitled “Caspase-1 inhibition and uses thereof for prevention and treatment of neurological conditions” to Andréa LeBlanc, as inventor, on November 2, 2021. This patent has been assigned to CASP-AID INC. and is pending in several additional countries. The results presented in this manuscript are not part of this patent (published or pending) nor was the work supported by CASP-AID INC. However, the results in the present manuscript showing the effect of VX-765 on cognition supports the claims of Patent 11,160,788.
: All animal protocols followed the Canadian Council on Animal Care guidelines approved by the Comité de Déontologie de l’Expérimentation sur les Animaux (CDEA, Université de Montréal) (Protocol # 21-044) and McGill University Animal Care committee (Protocol # 2014-7558).